JAGUAR HEALTH, INC. Increase (Decrease) in Deferred Revenue
JAGUAR HEALTH, INC. (JAGX) reported Increase (Decrease) in Deferred Revenue of $1.50 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2021-08-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2021-08-13
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$224.45K.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $39.77K.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$23.58K.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$16.20K, a 159.70% decline year-over-year.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for fiscal 2017 was -$224.45K.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for fiscal 2016 was -$27.48K, a 112.05% decline from fiscal 2015.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for fiscal 2015 was $228.13K, a 858.47% increase from fiscal 2014.
- JAGUAR HEALTH, INC. increase (decrease) in deferred revenue for fiscal 2014 was $23.80K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2020-06-30 | $1.50M 10-Q · filed 2021-08-13 | |||
| 2017-12-31 | -$224.45K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$184.67K derived: sum of 2 quarters · filed 2018-04-09 | -$208.26K derived: sum of 3 quarters · filed 2018-04-09 | -$224.45K 10-K · filed 2018-04-09 |
| 2017-09-30 | $39.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $16.19K derived: sum of 2 quarters · filed 2017-11-20 | -$6.00 10-Q · filed 2017-11-20 | -$21.79K derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-06-30 | -$23.58K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | -$39.78K 10-Q · filed 2017-08-09 | -$61.56K derived: sum of 3 quarters · filed 2018-04-09 | -$77.99K derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-03-31 | -$16.20K 10-Q/A · filed 2017-06-23 | -$37.98K derived: sum of 2 quarters · filed 2018-04-09 | -$54.41K derived: sum of 3 quarters · filed 2018-04-09 | -$70.81K derived: sum of 4 quarters · filed 2018-04-09 |
| 2016-12-31 | -$21.78K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$38.21K derived: sum of 2 quarters · filed 2018-04-09 | -$54.61K derived: sum of 3 quarters · filed 2018-04-09 | -$27.48K 10-K · filed 2018-04-09 |
| 2016-09-30 | -$16.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | -$32.83K derived: sum of 2 quarters · filed 2017-11-20 | -$5.70K 10-Q · filed 2017-11-20 | -$90.48K derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | -$16.40K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | $10.73K 10-Q · filed 2017-08-09 | -$74.05K derived: sum of 3 quarters · filed 2017-08-09 | -$110.93K derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $27.13K 10-Q/A · filed 2017-06-23 | -$57.65K derived: sum of 2 quarters · filed 2017-06-23 | -$94.53K derived: sum of 3 quarters · filed 2017-06-23 | -$109.88K derived: sum of 4 quarters · filed 2017-06-23 |
| 2015-12-31 | -$84.78K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | -$121.66K derived: sum of 2 quarters · filed 2017-02-15 | -$137.00K derived: sum of 3 quarters · filed 2017-02-15 | $228.13K 10-K · filed 2017-02-15 |
| 2015-09-30 | -$36.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$52.23K derived: sum of 2 quarters · filed 2016-11-14 | $312.91K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$15.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $349.79K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $365.14K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $23.80K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |